Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 3

Research Article

Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry

Table 3

Patients with [Na+] ≥5 mmol/L in response to initial and secondary .

Day 2
Day 3
Final response

Initial therapy, n (%)
NST9 (27)11 (33)13 (39)
FR29 (27)38 (36)42 (39)
NS54 (45)61 (51)62 (52)
HS7 (78)7 (78)7 (78)
TO10 (48)15 (71)17 (81)

Secondary therapy, n (%)
NST5 (36)5 (36)5 (36)
FR15 (31)18 (37)18 (37)
NS9 (29)10 (32)10 (32)
HS10 (100)10 (100)10 (100)
TO15 (58)17 (65)18 (68)

with initial moderate or severe hyponatremia.
Initial therapy P <0.05 for Day 2 response: no specific therapy (NST) vs hypertonic saline (HS), and fluid restriction (FR) vs HS and isotonic saline (NS); Day 3 response: NST vs HS and tolvaptan (TO); FR vs HS, NS, and TO: final response: NST vs TO, FR vs HS and TO, and NS vs TO.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.